Development Center for Biotechnology

National Health Research Institutes

Dcb-usa LLC

Shih-Chong Tsai

Ko-Jiunn Liu

Neng-Yao Shih

Ta-Tung Yuan

Li-Tzong Chen

Shih-Chi Tseng

Chao-Yang Huang

Shih-Hsien Chuang

Jiann-Shiun Lai

Ying-Yung Lok

Chia-Cheng Wu

Win-Yin Wei

Chung-Hsiun Wu

Ya-Wei Tsai

Hsin-Yun Wang

Chun-Chung Lee

Yi-Jen Chen

Chih-Yung Hu

Cheng-Chou Yu

Wei-Ting Sun

Chun-Liang Lai

Wun-Huei Lin

Ying-Shuan Lailee

Hsien-Yu Tsai

Wei-Tso Chia

Shyi-Jou Chen

Mingl Chang

Po-Yin Lin

Ching-Yao Chen

Meng-Sheng Lee

The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker, respectively; wherein the payload A and the payload B are the same or different. A pharmaceutical composition comprises the immunoconjugate and a method for treating cancer are also provided in the disclosure.

Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof

A process for modifying glycoproteins is provided. The invention also provides a process for producing glycoprotein-payload conjugates, as well as the conjugates produced thereby.

Processes for preparing glycoprotein-drug conjugates

An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.

Antibodies specific to alpha-enolase and uses thereof

A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against ENO1. The antagonist binds ENO1 and inhibits ENO1 plasminogen receptor activity. The antagonist may be an anti-human ENO1 antibody, or an scFv, Fab, or F(ab)fragment thereof, that specifically binds to human ENO1 (GenBank: AAH50642.1) for the treatment of an inflammatory disease or an immune disorder, which may be multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic Lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, type 1 diabetes mellitus, artherosclerosis or osteoporosis.

Alpha-enolase specific antibodies and method of use in immune diseases

A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy

The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19&#xd7;10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

Alpha-enolase specific antibodies and methods of uses in cancer therapy

Growing community of inventors

Taipei, Taiwan

Shih-Chong Tsai